First Turn Management’s BridgeBio Pharma BBIO Stock Holding History

First Turn Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.2M	Sell	633,364 -62,354	-9%	-$4.37M	5.05%	5
2026 Q1	$51.7M	Buy	695,718 +100,245	+17%	+$7.27M	5.77%	3
2025 Q4	$45.5M	Buy	595,473 +5,744	+1%	+$377K	5.2%	4
2025 Q3	$30.6M	Buy	589,729 +38,045	+7%	+$1.86M	4.6%	7
2025 Q2	$23.8M	Sell	551,684 -105,015	-16%	-$3.82M	4.44%	6
2025 Q1	$22.7M	Buy	656,699 +204,409	+45%	+$6.89M	4.58%	6
2024 Q4	$12.4M	Buy	452,290 +52,509	+13%	+$1.36M	2.22%	19
2024 Q3	$10.2M	Buy	+399,781	New	+$10.5M	1.61%	35

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

First Turn Management's BBIO Position: Q2 2026 in Review

First Turn Management reduced its BridgeBio Pharma (BBIO) stake by 9% in Q2 2026, selling an estimated $4.37M and leaving 633,364 shares worth $47.2M. The position accounts for 5.05% of the portfolio, ranked #5.

First Turn Management first reported a position in BBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $51.7M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

First Turn Management held 633,364 shares of BridgeBio Pharma worth $47.2M as of Q2 2026.
First Turn Management sold 62,354 BridgeBio Pharma shares in Q2 2026, an estimated $4.37M.
BridgeBio Pharma made up 5.05% of First Turn Management's portfolio in Q2 2026, its #5 holding.
First Turn Management first reported a position in BridgeBio Pharma in Q3 2024 and has held it in 8 quarters since.
First Turn Management's BridgeBio Pharma position peaked at $51.7M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.